Dabrafenib: the New Inhibitor of Hyperactive B-RAF Kinase
Authors:
P. Heneberg
Authors‘ workplace:
3. LF UK v Praze
Published in:
Klin Onkol 2012; 25(5): 333-339
Category:
Reviews
Overview
The B-RAF kinase is among major targets of biological therapy of cancer. B-RAF acts in the MAP kinase pathway, being activated by any of the RAS G-proteins. Hyperactive B-RAF is typically detected in chemoresistant and radioresistant malignant metastatic melanoma. In this study, we focus on the reversible ATP-competitive inhibitor dabrafenib (GSK-2118436), which is now in phase III clinical trial for use in subjects with various cancers expressing hyperactive B-RAF. Dabrafenib is selective for B-RAFV600E and B-RAFV600K (less for B-RAFV600D) over wild-type B-RAF. Thus, similarly to vemurafenib (Zelboraf), suggested is mandatory pre-screening for activating B-RAF mutations in the cancer tissue of each subject. Dabrafenib inhibits neoplastic growth at concentrations ≥ 53.8 nM in plasma, which corresponds to ≥ 30 mg/kg qd p.o., or to ≥ 3 mg/kg qd i.v. Most of the cancers expressing hyperactive B-RAF respond to dabrafenib treatment, but the complete response is only rarely achieved. Toxic side effects include skin lesions, pyrexia, frequent fatigue, nausea and pain. Resistance to dabrafenib is frequently developed via de novo RAS mutations, leading to the disease relapse. The RAS G-protein is capable of signaling downstream not only through B-RAF, but also through closely related C-RAF, which circumvents the effects of the B-RAF inhibitor. Thus, dabrafenib should not be prescribed to subjects with neoplasias that are positive for activating RAS mutations. Since B-RAF mutations alone cause only the formation of benign naevi, since the tumors frequently and quickly acquire resistance to B-RAF inhibitors, and because the B-RAF-inhibitor-mediated treatment outcomes are severely affected by changes in the activity and expression of a number of signaling molecules (among them PI3K/mTOR, PTEN, AKT, MEK, PDGFRβ), it can be anticipated that dabrafenib treatment should be suggested only as a part of combined therapy targeting simultaneously the other pathways responsible for cancer onset and progression.
Key words:
RAF1 – thyroid cancer – protein kinase inhibitors – antitumor agents – genetic predisposition to disease – neoplastic process – genetic markers – pharmacological biomarkers
Submitted:
29. 5. 2012
Accepted:
22. 8. 2012
Sources
1. Jailkhani N, Chaudhri VK, Rao KV. Regulatory cascades of protein phosphatases: implications for cancer treatment. Anticancer Agents Med Chem 2011; 11(1): 64–77.
2. Heneberg P. Pokroky v klinické léčbě zhoubného melanomu: inhibice kinázy B-RAF. Klin Onkol 2011; 24(4): 256–264.
3. Ferlay J, Shin HR, Bray F et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [online]. International Agency for Research on Cancer, Lyon, Francie; c2010 [aktualizováno 23. května 2012; citováno 23. května 2012]. Available from: http://globocan.iarc.fr.
4. Middleton MR, Lorigan P, Owen J et al. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 2000; 82(6): 1158–1162.
5. Chapman PB, Einhorn LH, Meyers ML et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17(9): 2745–2751.
6. Balch CA, Atkins MB, Sober AJ. Cutaneous melanoma. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds). Cancer, principles and practice of oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins 2005.
7. Hodis R, Watson IR, Kryukov GV et al. A landscape of driver mutations in melanoma. Cell 2012; 150(2): 251–263.
8. Houben R, Terheyden P, Bröecker EB et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 2004; 3(1): 6.
9. Long GV, Menzies AM, Nagrial AM et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29(10): 1239–1246.
10. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364(26): 2507–2516.
11. Chapman PB, Hauschild A, Robert C et al. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. J Clin Oncol 2012; 30: Abstrakt 8502.
12. Vyzula R, Adámková Krákorová D, Babjuk M et al. Zásady cytostatické léčby maligních onkologických onemocnění. 14th ed. Brno: Masarykův onkologický ústav 2012.
13. Šebek V. Léčivý přípravek Zelboraf byl registrován v EU pro léčbu pacientů s agresivní formou melanomu. Klin Onkol 2012; 25(2): 143–144.
14. Heneberg P. Dabrafenib, a small-molecule oral inhibitor of the mutant kinase BRAF for the potential treatment of cancer, in particular melanoma [online]. Thomson Reuters Pharma and Thomson Reuters Pharma Partnering databases; [aktualizováno 23. března 2012; citováno 23. března 2012]. Available from: https://partnering.thomson-pharma.com/partnering/partnering/.
15. Adams JL, Dickerson SH, Johnson NW et al. Benzene sulfonamide thiazole and oxazole compounds. International Patent claim WO/2009/137391 (podaný 6. 5. 2008), schválen v USA jako US-07994185, platný do ledna 2030.
16. King AJ, Arnone M, Moss K et al. A selective Raf Kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-Raf V600E mutation. San Francisco: 21st AACR-NCI-EORTC Int Congress, 17. 11. 2009: Abstrakt B88.
17. Ouellet D, Laquerre S, Minthorn E et al. Predictions of therapeutic doses of a B-Raf inhibitor, GSK2118436, based on exposure-response modeling of preclinical tumor biomarker and xenograft data. Orlando: 102nd Am Assoc Cancer Res Ann Meet, 6. 4. 2011: Abstrakt 5035.
18. Infante J, Falchook G, Lawrence D et al. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK-1120212 dosed in combination with the oral BRAF inhibitor GSK-2118436. Chicago: 47th Am Soc Clin Oncol Ann Meet, 6. 6. 2011: Abstrakt CRA8503.
19. GlaxoSmithKline PLC. Study BRF113468: An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects with BRAF Mutation-Positive Tumor. GSK Clinical Study Register 2012.
20. Kefford R, Arkenau H, Brown MP. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. Chicago: 46th Am Soc Clin Oncol Ann Meet, 5. 6. 2010: Abstrakt 8503.
21. GlaxoSmithKline PLC. Study BRF112680: A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the BRAF Inhibitor GSK2118436 in Subjects with Solid Tumors. GSK Clin Study Register 2012.
22. Azer MW, Menzies AM, Haydu L et al. Patterns of progression in patients (pts) with V600 BRAF-mutated melanoma metastatic to the brain treated with dabrafenib (GSK2118436). J Clin Oncol 2012; 30: Abstrakt 8558.
23. Kirkwood JM, Long GV, Trefzer U et al. BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/K mutation-positive melanoma with brain metastases (mets). J Clin Oncol 2012; 30: Abstrakt 8501.
24. Prahallad A, Sun C, Huang S et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483(7387): 100–103.
25. Corcoran RB, Falchook GS, Infente JR et al. BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212). J Clin Oncol 2012; 30: Abstrakt 3528.
26. Hauschild A, Grob JJ, Demidov LV et al. Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma. J Clin Oncol 2012; 30: Abstrakt LBA8500.
27. Kefford R. Selective inhibition of oncogenic BRAF V600E/K/D by GSK2118436: Evidence of clinical activity in subjects with metastatic melanoma. Florida: 7th Int Melanoma Res Congress, 5. 11. 2010.
28. Anforth R, Blumetti T, Kefford R et al. Cutaneous manifestations of the selective BRAF inhibitor GSK2118436 phase I/II. Australas J Dermatol 2011; 52: 10.
29. Weber JS, Flaherty KT, Infante JR et al. Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma. J Clin Oncol 2012; 30: Abstrakt 8510.
30. Long GV, Ascierto PA, Grob JJ et al. Tumor-specific circulating cell-free DNA (cfDNA) BRAF mutations (muts) to predict clinical outcome in patients (pts) treated with the BRAF inhibitor dabrafenib (GSK2118436). J Clin Oncol 2012; 30: Abstrakt 8518.
31. Nazarian R, Shi H, Wang Q et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468(7326): 973–977.
32. Cichowski K, Jänne PA. Drug discovery: inhibitors that activate. Nature 2010; 464(7287): 358–359.
33. Nathanson KL, Martin A, Letrero R et al. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor GSK-2118436 (GSK-436). Chicago: 47th Am Soc Clin Oncol Ann Meet, 6. 6. 2011: Abstrakt 8501.
34. Villanueva J, Vultur A, Lee JT et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinases switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010; 18(6): 683–695.
35. Ascierto PA, Gentilcore G, Madonna G et al. Are GSK2118436 and GSK1120212 effective in melanoma cell lines harboring V600BRAF mutations different from the common V600EBRAF variant? Eur J Cancer 2011; 47: S11.
36. Greger JG Jr, Eastman SD, Zhang V et al. Acquired resistance to the BRAF inhibitor GSK2118436, mediated by NRAS or MEK mutation, can be overcome with combinations that inhibit BRAF and MEK, BRAF and PI3K/mTOR, or MEK and PI3K/mTOR. Florida: 23rd AACR-NCI-EORTC Int Congress, 14. 11. 2011: Abstrakt B71.
37. Michaloglou C, Vredeveld LC, Soengas MS et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005; 436(7051): 720–724.
38. Arkenau HT, Kefford R, Long GV. Targeting BRAF for patients with melanoma. Br J Cancer 2011; 104(3): 392–398.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2012 Issue 5
Most read in this issue
- Uterine Sarcomas – a Review
- Analysis of Prognostic Factors in Osteosarcoma Adult Patients, a Single Institution Experience
- Bloodstream Infections of the Intravascular Access Devices – Case Reports and Review of the Literature
- BRAF Mutation: a Novel Approach in Targeted Melanoma Therapy